{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:24:38Z","timestamp":1784939078485,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Government-wide R&D Fund project for Infectious Disease research (GFID), Republic of Korea","award":["HG18C0068"],"award-info":[{"award-number":["HG18C0068"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.vaccine.2020.04.007","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:57:45Z","timestamp":1586393865000},"page":"3702-3710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Bacillus Calmette\u2013Gu\u00e9rin (BCG) vaccine safety surveillance in the Korea Adverse Event Reporting System using the tree-based scan statistic and conventional disproportionality-based algorithms"],"prefix":"10.1016","volume":"38","author":[{"given":"Ju Hwan","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyesung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.04.007_b0005","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.tube.2009.03.002","article-title":"Mapping the global use of different BCG vaccine strains","volume":"89","author":"Ritz","year":"2009","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.vaccine.2020.04.007_b0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2223\/1146","article-title":"Percutaneous or intradermal BCG vaccine?","volume":"80","author":"Bricks","year":"2004","journal-title":"J Pediatr (Rio J)"},{"key":"10.1016\/j.vaccine.2020.04.007_b0015","unstructured":"hma.edu. BCG vaccine SSI - Summary of Product Characteristics (SPC); 2015. [online] Available at: http:\/\/mri.cts-mrp.eu\/download\/DK_H_0367_001_FinalPL_2of2.pdf [accessed 17 Sep. 2019]."},{"key":"10.1016\/j.vaccine.2020.04.007_b0020","unstructured":"BCG vaccine for percutaneous use [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2019."},{"key":"10.1016\/j.vaccine.2020.04.007_b0025","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2019.34.e3","article-title":"Mycobacterium bovis Osteitis following immunization with Bacille Calmette-Guerin (BCG) in Korea","volume":"34","author":"Choi","year":"2019","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.vaccine.2020.04.007_b0030","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.vaccine.2017.12.010","article-title":"Bacillus Calmette-Guerin (BCG) vaccine: A global assessment of demand and supply balance","volume":"36","author":"Cernuschi","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.04.007_b0035","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1473-3099(02)00182-2","article-title":"BCG\u2014different strains, different vaccines?","volume":"2","author":"Behr","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.04.007_b0040","first-page":"337","article-title":"Safety of the intradermal Copenhagen 1331 BCG vaccine in neonates in Durban, South Africa","volume":"79","author":"Jeena","year":"2001","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2020.04.007_b0045","doi-asserted-by":"crossref","first-page":"6967","DOI":"10.1016\/j.vaccine.2009.09.073","article-title":"Local and regional adverse reactions to BCG-SSI vaccination: a 12-month cohort follow-up study","volume":"27","author":"Dommergues","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.04.007_b0050","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4103\/0377-4929.97869","article-title":"Bacillus Calmette-Guerin lymphadenitis: A 6-year experience in two Saudi hospitals","volume":"55","author":"Bukhari","year":"2012","journal-title":"Indian J Pathol Microbiol"},{"key":"10.1016\/j.vaccine.2020.04.007_b0055","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.vaccine.2016.03.100","article-title":"Adverse reactions to the Bacillus Calmette-Guerin (BCG) vaccine in new-born infants-an evaluation of the Danish strain 1331 SSI in a randomized clinical trial","volume":"34","author":"Nissen","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.04.007_b0060","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.a2052","article-title":"Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial","volume":"337","author":"Hawkridge","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2020.04.007_b0065","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2020.04.007_b0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2020.04.007_b0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.vaccine.2020.04.007_b0080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"Dumouchel","year":"1999","journal-title":"Am Statist"},{"key":"10.1016\/j.vaccine.2020.04.007_b0085","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/1541-0420.00039","article-title":"A tree-based scan statistic for database disease surveillance","volume":"59","author":"Kulldorff","year":"2003","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2020.04.007_b0090","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/pds.3423","article-title":"Drug safety data mining with a tree-based scan statistic","volume":"22","author":"Kulldorff","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2020.04.007_b0095","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1093\/aje\/kwy023","article-title":"Assessment of quadrivalent human papillomavirus vaccine safety using the self-controlled tree-temporal scan statistic signal-detection method in the sentinel system","volume":"187","author":"Yih","year":"2018","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2020.04.007_b0100","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/pds.4397","article-title":"Meningococcal conjugate vaccine safety surveillance in the Vaccine Safety Datalink using a tree-temporal scan data mining method","volume":"27","author":"Li","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2020.04.007_b0105","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40264-018-00784-0","article-title":"An implementation and visualization of the tree-based scan statistic for safety event monitoring in longitudinal electronic health data","volume":"42","author":"Schachterle","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2020.04.007_b0110","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/pharmaceutics5010179","article-title":"Drug adverse event detection in health plan data using the gamma poisson shrinker and comparison to the tree-based scan statistic","volume":"5","author":"Brown","year":"2013","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.vaccine.2020.04.007_b0115","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/pds.3715","article-title":"New initiatives for pharmacovigilance in South Korea: introducing the Korea Institute of Drug Safety and Risk Management (KIDS)","volume":"23","author":"Shin","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2020.04.007_b0120","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00002018-199410020-00001","article-title":"Harmonisation in pharmacovigilance","volume":"10","author":"Edwards","year":"1994","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2020.04.007_b0125","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2020.04.007_b0130","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.vaccine.2020.04.007_b0135","unstructured":"HCUP CCS. Healthcare Cost and Utilization Project (HCUP). March 2017. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov\/toolssoftware\/ccs\/ccs.jsp."},{"key":"10.1016\/j.vaccine.2020.04.007_b0140","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2020.04.007_b0145","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40264-013-0051-9","article-title":"Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010\u20132011 seasonal influenza virus vaccine","volume":"36","author":"Martin","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2020.04.007_b0150","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.vaccine.2018.02.034","article-title":"Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009\u20132015","volume":"36","author":"Arana","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.04.007_b0155","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.vaccine.2016.03.048","article-title":"Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015","volume":"34","author":"Haber","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.04.007_b0160","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40264-014-0204-5","article-title":"Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank","volume":"37","author":"Caster","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2020.04.007_b0165","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40264-014-0248-6","article-title":"Bacillus Calmette-Guerin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system","volume":"38","author":"Clothier","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2020.04.007_b0170","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1016\/j.vaccine.2018.05.098","article-title":"Clinical features and outcomes of Bacille Calmette-Guerin (BCG)-induced diseases following neonatal BCG Tokyo-172 strain immunization","volume":"36","author":"Rermruay","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.04.007_b0175","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4046\/trd.2012.72.4.374","article-title":"The current status of BCG vaccination in Young Children in South Korea","volume":"72","author":"Lee","year":"2012","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"10.1016\/j.vaccine.2020.04.007_b0180","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1136\/bmj.297.6657.1173-a","article-title":"BCG immunisation of infants by percutaneous multiple puncture","volume":"297","author":"Cundall","year":"1988","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2020.04.007_b0185","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/thx.54.9.762","article-title":"Administration of the BCG vaccination using the multipuncture method in schoolchildren: a comparison with the intradermal method","volume":"54","author":"Al Jarad","year":"1999","journal-title":"Thorax"},{"key":"10.1016\/j.vaccine.2020.04.007_b0190","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/adc.63.12.1491","article-title":"Tuberculin response after neonatal BCG vaccination","volume":"63","author":"Ormerod","year":"1988","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2020.04.007_b0195","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/adc.69.1.155","article-title":"Tuberculin reactivity after neonatal percutaneous BCG immunisation","volume":"69","author":"Ormerod","year":"1993","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2020.04.007_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164792","article-title":"Differential adverse event profiles associated with BCG as a preventive tuberculosis vaccine or therapeutic bladder cancer vaccine identified by comparative ontology-based VAERS and literature meta-analysis","volume":"11","author":"Xie","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.04.007_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3960\/jslrt.52.1","article-title":"Granulomatous lymphadenitis","volume":"52","author":"Asano","year":"2012","journal-title":"J Clin Exp Hematopathol"},{"key":"10.1016\/j.vaccine.2020.04.007_b0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jctube.2017.02.001","article-title":"Histopathologic review of granulomatous inflammation","volume":"7","author":"Shah","year":"2017","journal-title":"J Clin Tuberculosis Other Mycobact Dis"},{"key":"10.1016\/j.vaccine.2020.04.007_b0215","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/01.inf.0000164769.22033.2c","article-title":"Serious adverse events associated with bacille Calmette-Guerin vaccine in Canada","volume":"24","author":"Deeks","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.04.007_b0220","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1086\/513642","article-title":"Disseminated bacille Calmette-Guerin disease after vaccination: case report and review","volume":"24","author":"Talbot","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.04.007_b0225","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jpeds.2018.11.042","article-title":"Clinical manifestations, management, and outcomes of osteitis\/osteomyelitis caused by Mycobacterium bovis Bacillus Calmette-Guerin in Children: comparison by site(s) of affected bones","volume":"207","author":"Huang","year":"2019","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2020.04.007_b0230","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00006454-199402000-00007","article-title":"Osteitis after newborn vaccination with three different Bacillus Calmette-Guerin vaccines: twenty-nine years of experience","volume":"13","author":"Kroger","year":"1994","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.04.007_b0235","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40264-015-0289-5","article-title":"Comparison of statistical signal detection methods within and across spontaneous reporting databases","volume":"38","author":"Candore","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2020.04.007_b0240","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/clpt.2013.24","article-title":"Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system","volume":"93","author":"Harpaz","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.vaccine.2020.04.007_b0245","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40264-012-0002-x","article-title":"A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases","volume":"36","author":"Coloma","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2020.04.007_b0250","first-page":"46","article-title":"Comparison of WHO-ART versus MedDRA, internationallystandardized terminology of adverse drug reaction classification","volume":"17","author":"Kyung Hwa","year":"2007","journal-title":"Korean J Clin Pharm"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20304667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20304667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:43:54Z","timestamp":1759401834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20304667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":50,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0264410X20304667"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.04.007","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bacillus Calmette\u2013Gu\u00e9rin (BCG) vaccine safety surveillance in the Korea Adverse Event Reporting System using the tree-based scan statistic and conventional disproportionality-based algorithms","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}